Ambulero, Inc.

Ambulero, Inc. develops innovative cell and gene therapies for vascular diseases, focusing on engineered stromal cells that enhance tissue repair and gene therapies for targeted delivery. Founded in 2019 and headquartered in Miami, US, Ambulero, Inc. specializes in therapies targeting vascular diseases.

The company secured USD 5. 5 mn in Seed funding led by Orphinic Scientific on January 25, 2021, marking its first investment round. Robert Buchanan is the founder, bringing his experience from previous ventures to lead this innovative company. Ambulero, Inc.

specializes in innovative cell and gene therapies aimed at addressing vascular disease. The company’s primary offerings include engineered stromal cells, referred to as 'supercharged' mesenchymal stem cells (MSCs), designed to express the cell adhesion molecule E-selectin. These cells exhibit exceptional tissue repair capabilities in animal models, providing a novel solution for injuries related to vascular diseases. Additionally, Ambulero is advancing a gene therapy approach that delivers the E-selectin molecule to damaged tissues via established gene therapy vectors, targeting patients with rare vascular ischemia, particularly among younger individuals.

Ambulero's revenue model is centered around partnerships and collaborations within the healthcare sector, particularly focusing on clinical trials and the development of proprietary therapies. The company engages with healthcare institutions and research organizations to advance its innovative products, establishing agreements based on revenue-sharing or milestone payments linked to successful clinical outcomes. Ambulero's flagship products, including supercharged MSCs and E-selectin gene therapy, are strategically marketed to hospitals and specialized medical providers catering to patients with vascular diseases, generating pathways for direct sales and contract-based revenue streams. Ambulero, Inc.

plans to leverage the recent Seed funding of USD 5. 5 mn to accelerate the development of its innovative therapies and expand into new markets across North America and Europe by 2023. The company is actively designing upcoming products, including advancements in its gene therapy approach, aiming to enhance treatment options for vascular diseases. The funding will support clinical trials and the establishment of strategic collaborations to facilitate market entry and distribution channels for its therapies.